Skip to main content
Erschienen in: Supportive Care in Cancer 8/2018

12.03.2018 | Original Article

TOXICAN: a guide for grading dermatological adverse events of cancer treatments

verfasst von: L. Peuvrel, J. Cassecuel, C. Bernier, G. Quéreux, M. Saint-Jean, M. Le Moigne, C. Frénard, A. Khammari, B. Dréno, Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The dermatological toxicity of cancer treatments is frequent and sometimes debilitating. Its reference classification, the NCI-CTCAE (National Cancer Institute–Common Terminology Criteria for Adverse Events), is sometimes difficult to use and does not include yet the newest toxicities. Our objective was to create a guide, TOXICAN, based on the CTCAE, which is easy to use in everyday practice and which facilitates the recognition and grading of these dermatological toxicities.

Methods

This guide was developed by a working group (“GESTIM”) comprising oncodermatologists, allergists, pathologists, and researchers from Nantes University Hospital. It was based on the dermatological toxicities found in the CTCAE and adapted to daily practice. These toxicities were grouped into categories and associated with photographs of typical cases to aid recognition. A simplified grading scale derived from the CTCAE was also created. This booklet was validated by means of user evaluation, and then the Delphi consensus method.

Results

We selected 32 dermatological toxicities, including 12 created by our group, sorted into 7 categories: skin rash, dry skin/pruritus, hyperkeratotic papules, palmoplantar changes, hair and nail changes, mucosal changes, and others. Our simplified grading scale only differed from the CTCAE for one item, urticaria. Three items were modified after evaluation by the user group and 11 after application of the Delphi method.

Conclusion

The objective of our practical guide is to facilitate the use of the CTCAE for recognizing and grading dermatological toxicity of cancer treatments in order to provide optimal guidance for therapeutic adaptations. Its impact on clinical practice remains to be evaluated.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181CrossRefPubMed Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181CrossRefPubMed
2.
Zurück zum Zitat Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gonen M, Schrag D, Basch E (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21(7):1159–1164CrossRefPubMed Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gonen M, Schrag D, Basch E (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21(7):1159–1164CrossRefPubMed
3.
Zurück zum Zitat Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C, Licitra L, Scaramellini G, Cantu G, Olmi P (2008) Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. Int J Radiat Oncol Biol Phys 70(2):330–337CrossRefPubMed Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C, Licitra L, Scaramellini G, Cantu G, Olmi P (2008) Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. Int J Radiat Oncol Biol Phys 70(2):330–337CrossRefPubMed
4.
Zurück zum Zitat Jiang G, Wang L, Liu H, Solbrig HR, Chute CG (2013) Building a knowledge base of severe adverse drug events based on AERS reporting data using semantic web technologies. Stud Health Technol Inform 192:496–500PubMed Jiang G, Wang L, Liu H, Solbrig HR, Chute CG (2013) Building a knowledge base of severe adverse drug events based on AERS reporting data using semantic web technologies. Stud Health Technol Inform 192:496–500PubMed
5.
Zurück zum Zitat Bergman H, Walton T, Del Bel R, Seki JT, Rafii A, Xu W, Koren G, Shear N, Krzyzanowska MK, Howell D, Liu G (2014) Managing skin toxicities related to panitumumab. J Am Acad Dermatol 71(4):754–759CrossRefPubMed Bergman H, Walton T, Del Bel R, Seki JT, Rafii A, Xu W, Koren G, Shear N, Krzyzanowska MK, Howell D, Liu G (2014) Managing skin toxicities related to panitumumab. J Am Acad Dermatol 71(4):754–759CrossRefPubMed
6.
Zurück zum Zitat Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509–522CrossRefPubMed Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509–522CrossRefPubMed
7.
Zurück zum Zitat Chan A, Tan EH (2011) How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer 19(10):1667–1674CrossRefPubMed Chan A, Tan EH (2011) How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer 19(10):1667–1674CrossRefPubMed
8.
Zurück zum Zitat Sibaud V, Delord JP, Robert C (2015) Dermatology and anticancer therapies: practical handbook. Editions Privat, Toulouse Sibaud V, Delord JP, Robert C (2015) Dermatology and anticancer therapies: practical handbook. Editions Privat, Toulouse
9.
Zurück zum Zitat Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610–621CrossRefPubMed Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610–621CrossRefPubMed
10.
Zurück zum Zitat Gonzalez-Sanchis A, Vicedo-Gonzalez A, Brualla-Gonzalez L, Gordo-Partearroyo JC, Inigo-Valdenebro R, Sanchez-Carazo J, Granero-Cabanero D, Rosello-Ferrando J, Lopez-Torrecilla J (2014) Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations. Clin Transl Oncol 16(10):892–897CrossRefPubMed Gonzalez-Sanchis A, Vicedo-Gonzalez A, Brualla-Gonzalez L, Gordo-Partearroyo JC, Inigo-Valdenebro R, Sanchez-Carazo J, Granero-Cabanero D, Rosello-Ferrando J, Lopez-Torrecilla J (2014) Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations. Clin Transl Oncol 16(10):892–897CrossRefPubMed
11.
Zurück zum Zitat Liu YJ, Zhu GP, Guan XY (2012) Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol 48(6):554–559CrossRefPubMed Liu YJ, Zhu GP, Guan XY (2012) Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol 48(6):554–559CrossRefPubMed
12.
Zurück zum Zitat Deng J, Ridner SH, Dietrich MS, Wells N, Murphy BA (2013) Assessment of external lymphedema in patients with head and neck cancer: a comparison of four scales. Oncol Nurs Forum 40(5):501–506CrossRefPubMed Deng J, Ridner SH, Dietrich MS, Wells N, Murphy BA (2013) Assessment of external lymphedema in patients with head and neck cancer: a comparison of four scales. Oncol Nurs Forum 40(5):501–506CrossRefPubMed
13.
Zurück zum Zitat Eisbruch A, Rhodus N, Rosenthal D, Murphy B, Rasch C, Sonis S, Scarantino C, Brizel D (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13(3):226–234CrossRefPubMed Eisbruch A, Rhodus N, Rosenthal D, Murphy B, Rasch C, Sonis S, Scarantino C, Brizel D (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13(3):226–234CrossRefPubMed
14.
Zurück zum Zitat Peuvrel L, Dreno B (2014) Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol 15(5):425–444CrossRefPubMed Peuvrel L, Dreno B (2014) Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol 15(5):425–444CrossRefPubMed
15.
Zurück zum Zitat Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095CrossRefPubMedPubMedCentral Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Russo AL, Taghian AG (2013) Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system. Breast Cancer Res Treat 140(1):1–11CrossRefPubMed Russo AL, Taghian AG (2013) Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system. Breast Cancer Res Treat 140(1):1–11CrossRefPubMed
17.
Zurück zum Zitat Fine LM, Bernstein JA (2015) Urticaria guidelines: consensus and controversies in the European and American guidelines. Curr Allergy Asthma Rep 15(6):30CrossRefPubMed Fine LM, Bernstein JA (2015) Urticaria guidelines: consensus and controversies in the European and American guidelines. Curr Allergy Asthma Rep 15(6):30CrossRefPubMed
18.
Zurück zum Zitat Williams KW, Sharma HP (2015) Anaphylaxis and urticaria. Immunol Allergy Clin N Am 35(1):199–219CrossRef Williams KW, Sharma HP (2015) Anaphylaxis and urticaria. Immunol Allergy Clin N Am 35(1):199–219CrossRef
19.
Zurück zum Zitat Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol 72(2):203–218 quiz 219-220CrossRefPubMed Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol 72(2):203–218 quiz 219-220CrossRefPubMed
20.
Zurück zum Zitat Zenda S, Ota Y, Tachibana H, Ogawa H, Ishii S, Hashiguchi C, Akimoto T, Ohe Y, Uchitomi Y (2016) A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients. J Radiat Res 57(3):301–306CrossRefPubMedPubMedCentral Zenda S, Ota Y, Tachibana H, Ogawa H, Ishii S, Hashiguchi C, Akimoto T, Ohe Y, Uchitomi Y (2016) A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients. J Radiat Res 57(3):301–306CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Lencioni A, Hutchins L, Annis S, Chen W, Ermisoglu E, Feng Z, Mack K, Simpson K, Lane C, Topaloglu U (2015) An adverse event capture and management system for cancer studies. BMC Bioinformatics 16(Suppl 13):S6CrossRefPubMedPubMedCentral Lencioni A, Hutchins L, Annis S, Chen W, Ermisoglu E, Feng Z, Mack K, Simpson K, Lane C, Topaloglu U (2015) An adverse event capture and management system for cancer studies. BMC Bioinformatics 16(Suppl 13):S6CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9) Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9)
23.
Zurück zum Zitat Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E (2015) Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051–1059CrossRefPubMedPubMedCentral Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E (2015) Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051–1059CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, Schrag D, Basch E (2014) Cognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23(1):257–269CrossRefPubMed Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, Schrag D, Basch E (2014) Cognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23(1):257–269CrossRefPubMed
25.
Zurück zum Zitat Kluetz PG, Chingos DT, Basch EM, Mitchell SA (2016) Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 35:67–73CrossRefPubMed Kluetz PG, Chingos DT, Basch EM, Mitchell SA (2016) Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 35:67–73CrossRefPubMed
Metadaten
Titel
TOXICAN: a guide for grading dermatological adverse events of cancer treatments
verfasst von
L. Peuvrel
J. Cassecuel
C. Bernier
G. Quéreux
M. Saint-Jean
M. Le Moigne
C. Frénard
A. Khammari
B. Dréno
Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments
Publikationsdatum
12.03.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4153-x

Weitere Artikel der Ausgabe 8/2018

Supportive Care in Cancer 8/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.